T. Rowe Price Associates
AMLX icon

T. Rowe Price Associates’s Amylyx Pharmaceuticals AMLX Stock Holding History

T. Rowe Price Associates’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61M Buy
145,133
+23,694
+20% +$366K ﹤0.01% 1885
2026
Q1 		$1.69M Buy
121,439
+13,891
+13% +$195K ﹤0.01% 1905
2025
Q4 		$1.3M Buy
107,548
+7,103
+7% +$96.5K ﹤0.01% 1966
2025
Q3 		$1.37M Buy
100,445
+9,053
+10% +$85.2K ﹤0.01% 1917
2025
Q2 		$586K Buy
91,392
+33,692
+58% +$164K ﹤0.01% 2231
2025
Q1 		$205K Hold
57,700
– – ﹤0.01% 2618
2024
Q4 		$219K Buy
57,700
+2,100
+4% +$9.88K ﹤0.01% 2640
2024
Q3 		$181K Hold
55,600
– – ﹤0.01% 2686
2024
Q2 		$106K Sell
55,600
-914,955
-94% -$1.77M ﹤0.01% 2752
2024
Q1 		$2.76M Buy
970,555
+75,775
+8% +$991K ﹤0.01% 1428
2023
Q4 		$13.2M Buy
894,780
+870,560
+3,594% +$13.3M ﹤0.01% 1042
2023
Q3 		$444K Buy
24,220
+1,132
+5% +$23.9K ﹤0.01% 2163
2023
Q2 		$499K Buy
23,088
+581
+3% +$15.7K ﹤0.01% 2135
2023
Q1 		$661K Buy
22,507
+6,824
+44% +$237K ﹤0.01% 1989
2022
Q4 		$579K Buy
+15,683
New +$557K ﹤0.01% 2070

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates's AMLX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Amylyx Pharmaceuticals (AMLX) stake by 20% in Q2 2026, buying an estimated $366K and bringing the position to 145,133 shares worth $2.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1885.

T. Rowe Price Associates first reported a position in AMLX in Q4 2022 and has held it in 15 quarters since. The position peaked at $13.2M in Q4 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • T. Rowe Price Associates held 145,133 shares of Amylyx Pharmaceuticals worth $2.61M as of Q2 2026.
  • T. Rowe Price Associates bought 23,694 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $366K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1885 holding.
  • T. Rowe Price Associates first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • T. Rowe Price Associates's Amylyx Pharmaceuticals position peaked at $13.2M in Q4 2023.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.